Knowledge Hub
Dr. R. Brahmananda Reddy
6 April 2026

If you have ever had a cholesterol test, you are familiar with the usual suspects: total cholesterol, LDL, HDL, and triglycerides. But there is a fifth player that most standard panels completely ignore — and it may be the most important one on the entire report.
Its name is Apolipoprotein B, or ApoB for short. And once you understand what it measures, you will never look at a lipid panel the same way again.
Every atherogenic lipoprotein particle — the kind that can burrow into your artery walls and start the process of plaque formation — carries exactly one ApoB protein on its surface. That includes LDL particles, VLDL particles, IDL particles, and lipoprotein(a).
When you measure ApoB, you are counting every single particle capable of causing atherosclerosis. LDL cholesterol, by contrast, measures the amount of cholesterol carried inside LDL particles — not the number of particles themselves.
Why does the distinction matter? Because two people with identical LDL-C values can have vastly different particle counts. The person with more particles has more "arrows" aimed at their arterial walls.
A 2021 meta-analysis published in JAMA Cardiology involving over 900,000 participants concluded that ApoB was a stronger predictor of myocardial infarction and cardiovascular events than LDL-C, non-HDL-C, or any other standard lipid measure. The European Atherosclerosis Society now recommends ApoB as the primary target for lipid-lowering therapy.
In practical terms: if your LDL-C looks "normal" at 100 mg/dL but your ApoB is elevated at 110 mg/dL, you may have discordance — a mismatch that signals hidden risk your standard panel completely missed.
Frankly, everyone deserves to know their ApoB level at least once. But it is especially critical for individuals with metabolic syndrome, insulin resistance, type 2 diabetes, elevated triglycerides, or a family history of premature heart disease. In these groups, LDL-C frequently underestimates true atherogenic risk.
Standard cardiology guidelines suggest keeping ApoB below 130 mg/dL for low-risk individuals and below 80 mg/dL for high-risk patients. But in longevity medicine, we aim higher — or rather, lower. Many longevity-focused physicians target an ApoB of 60 mg/dL or below, based on Mendelian randomization studies showing that lifelong low ApoB exposure dramatically reduces cardiovascular events.
At GenoRyx, we include ApoB as a standard component of our advanced biomarker panels. We do not believe in incomplete pictures when your vascular health is at stake. If your last cholesterol report did not include ApoB, it may be time for a more thorough look. Schedule a consultation to understand what your lipid particles are truly doing.
Book your 400+ biomarker assessment — physician consultation included.
Schedule a consultationReady to know your numbers?
Schedule your consultation with our longevity physician team.
Book Your AssessmentWritten by
UK-trained physician and founder of Genoryx. Writes about longevity medicine, healthspan optimization, and evidence-based wellness.
View profile →
Learn why wearable VO2 Max data can be misleading. Discover how clinical VO2 Max testing in Hyderabad provides precision data for longevity and performance.

Your Apple Watch tracks your heart rate continuously. Your blood test measures it once a year. Both data streams have value, but neither tells the complete story alone.